BML, Inc.(BMLKF)
USD --+0.00%
Reward33Low
Risk37Moderate
📊75%Data
3.0% dividend yield
BMLKF
+0.0 · +0.00%
USD · PINK
BML, Inc. | Healthcare
Capital Destroyer
Market Cap:944.85M
ℹ️
Reward Rating
33
Low
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
37
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on BMLKF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is BML, Inc.?

provides contract clinical testing and related services in Japan.

BMLKF · Verdict

Limited reward · moderate risk

BMLKF's standout is volatility; profitability and growth weigh on the picture.

Based on 88% data coverage

BMLKF · Verdict

What’s working & what to watch

Strengths 1

  • Volatility95/100

    Top decile vs peers

Watchouts 2

  • Profitability15/100

    4% net margin · 6% ROE

  • Growth20/100

    Rev -8.4% CAGR · earnings -43.0%

Model-based scoring. For information only — not financial advice.

What is BML, Inc.?

provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 944.85M, and a P/E ratio of 22.1x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Low (33)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap944.85M
P/E Ratio22.1114
Dividend Yield2.98%
52 Week High25.207
52 Week Low19.2325
Last AnnualMarch
IPO DateN/A
IncorporatedUSA
Shares Outstanding37M
No. of Employees4,558
IndustryDiagnostics & Research
ExchangePINK
Beta0.21
CurrencyUSD · Reports in JPY